Treatment-induced motor complications represent a major clinical problem in Parkinson's disease (PD). Pharmacological dopamine (DA) replacement with l-dopa causes motor fluctuations and abnormal involuntary movements (dyskinesia) in the vast majority of the patients. Intrastriatal grafts of embryonic dopaminergic neurons can cause dyskinesia too, as shown by clinical trials of neural transplantation in PD. Animals models of these complications can be produced in rats and mice in which the nigrostriatal DA pathway has been severely damaged. Rodent models allow investigators to explore mechanistic hypotheses at the cellular and molecular level. Moreover, the rat model of L-dopa-induced abnormal involuntary movements shows both face validity a...
A common side effect of the pharmacotherapy for treatment of the movement disorder Parkinson’s disea...
The crucial role of dopamine (DA) in movement control is illustrated by the spectrum of motor disord...
Dyskinesia (abnormal involuntary movements) is a common complication of l-DOPA pharmacotherapy in Pa...
Parkinson’s disease is a movement disorder, caused predominantly by the degeneration of the dopamine...
Animal models of Parkinson’s disease and L-DOPA-induced dyskinesia are essential to explore pathophy...
Understanding the biological mechanisms of l-dopa-induced motor complications is dependent on our ab...
Major limitations to the pharmacotherapy of Parkinson's disease (PD) are the motor complications res...
Strategies to avoid or minimize dyskinesia and other motor complications of chronic dopamine replace...
The work presented in herein focuses on the optimisation and use of established animal models to stu...
Appearance of l-DOPA-induced dyskinesia (LID) represents a major limitation in the pharmacological t...
Dopamine replacement therapy effectively relieves the typical motor features of Parkinson disease (P...
Animal models of neurological deficits are essential to assess new therapeutic options and reduce tr...
Animal models of Parkinson's disease (PD) have proved highly effective in the discovery of novel tre...
Dyskinesia (abnormal involuntary movements) is a common complication of l-DOPA pharmacotherapy in Pa...
This unit provides detailed protocols for establishing rodent models of L-DOPA-induced dyskinesia. T...
A common side effect of the pharmacotherapy for treatment of the movement disorder Parkinson’s disea...
The crucial role of dopamine (DA) in movement control is illustrated by the spectrum of motor disord...
Dyskinesia (abnormal involuntary movements) is a common complication of l-DOPA pharmacotherapy in Pa...
Parkinson’s disease is a movement disorder, caused predominantly by the degeneration of the dopamine...
Animal models of Parkinson’s disease and L-DOPA-induced dyskinesia are essential to explore pathophy...
Understanding the biological mechanisms of l-dopa-induced motor complications is dependent on our ab...
Major limitations to the pharmacotherapy of Parkinson's disease (PD) are the motor complications res...
Strategies to avoid or minimize dyskinesia and other motor complications of chronic dopamine replace...
The work presented in herein focuses on the optimisation and use of established animal models to stu...
Appearance of l-DOPA-induced dyskinesia (LID) represents a major limitation in the pharmacological t...
Dopamine replacement therapy effectively relieves the typical motor features of Parkinson disease (P...
Animal models of neurological deficits are essential to assess new therapeutic options and reduce tr...
Animal models of Parkinson's disease (PD) have proved highly effective in the discovery of novel tre...
Dyskinesia (abnormal involuntary movements) is a common complication of l-DOPA pharmacotherapy in Pa...
This unit provides detailed protocols for establishing rodent models of L-DOPA-induced dyskinesia. T...
A common side effect of the pharmacotherapy for treatment of the movement disorder Parkinson’s disea...
The crucial role of dopamine (DA) in movement control is illustrated by the spectrum of motor disord...
Dyskinesia (abnormal involuntary movements) is a common complication of l-DOPA pharmacotherapy in Pa...